PGNY:NASDAQProgyny, Inc. Analysis

Progyny, Inc. (PGNY) is trading at $24.05, roughly 19% below its DCF‑derived fair value of $37.77, suggesting a material upside potential. The stock benefits from a strong earnings backdrop – Q1 revenue topped $328.5 M, profit margins expanded to 5.2%, and free cash flow exceeds $200 M, while the balance sheet remains robust with $225 M in cash and modest debt of $27 M. Technicals show a bullish MACD crossover (MACD line > signal line) but an elevated RSI at 74 points to short‑term overbought conditions near the $24.39 resistance level. Analyst sentiment is highly positive, with a consensus “strong buy” rating from 11 analysts and a median price target of $30. Key catalysts include ongoing share repurchases (8.8 M shares bought back), a raised 2026 revenue outlook of $1.365‑$1.405 B, and an expanding client base despite the loss of a large customer. While the market exhibits high 30‑day volatility (≈70%) and a neutral trend, the underlying fundamentals—steady revenue growth, solid cash generation, low debt‑to‑equity, and a favorable industry PE relative to peers—support a longer‑run upside thesis.